Painless BioXensor non-invasive continuous blood glucose monitor from GlucoRx undergoes further preparation for pending FDA and CE approval
The British company GlucoRx has offered up some news in regard to its work on a painless non-invasive continuous blood glucose monitor, which it has called the BioXensor. The device is undergoing more studies to assist with FDA and CE approval while also scheduled to make various appearances at exhibitions and conferences around the world. Apparently, the BioXensor CGM has already achieved a MARD (mean absolute relative difference) value of 10.4% in testing. Unlike many other startups chasing this particular medical “Holy Grail”, GlucoRx is already established in the diabetic care product sector and launched the UK’s first prescription CGM, the GlucoRx AiDEX, earlier this year.
The BioXensor blood sugar monitor appears to work in a similar way to many other devices in the same category. Instead of requiring needles and potentially painful and scarring finger sticking, the device is simply attached to the skin of the upper arm and utilizes a “patented radio frequency technology” to constantly measure the relevant biomarkers. GlucoRx is also preparing a BioXensor smart app to allow users and other family members to monitor levels and be warned about possible hypoglycemic or hyperglycemic episodes. The non-invasive BioXensor CGM reportedly measures blood glucose levels from under 2 mmol/L (hypoglycemic) to over 30 mmol/L (hyperglycemic).
There are no launch date or pricing details published yet for the BioXensor but GlucoRx does claim that the device will be “affordable”. It seems the company has been working on the non-invasive CGM for quite some time, with a first somewhat clunky-looking prototype having been put together back in 2012-2013. The current BioXensor is actually the fourth version, and it certainly looks the part in comparison to the older models (see images below). GlucoRx will be taking its multi-sensor device, which can also detect SpO2, hydration levels, and user falls along with blood glucose levels, on an exhibition tour that includes upcoming dates in Germany, the UK, the UAE, and the USA. The company also offers a newsletter for those who want to stay up to date with progress.